Diagnosis, Pathogenesis and Treatment of CNS Tumors (2nd Edition)

Dear Colleagues,

The current Classification of the Tumors of the Central Nervous System (CNS), published in 2021, not only incorporates histopathological features but also the molecular findings of some of the most common CNS tumors. In this context, the term ‘integrated diagnosis’ has been introduced, which refers to the combined use of these individual characteristics in the description of the final diagnosis.

Furthermore, several novel changes have affected both the nomenclature and grading of tumors. In particular, the former (i.e., terminology) is based on the recommendations of the 2019 cIMPACT-NOW Utrecht meeting, thus aiming to achieve better effectiveness and consistency. It also conforms with the HUGO Gene Nomenclature Committee (HGNC) system for gene symbols and names.

On the other hand, the recently developed grading system aims to comply with the one used for non-CNS neoplasms. More specifically, Roman numerals are replaced by Arabic numerals, which is similar to the grading of other organ systems. Additionally, grading is introduced within tumor types, which corresponds to a combined histological and molecular grading. As certain molecular markers have been found to correlate with prognosis, this fact has necessitated the inclusion of these markers in the lastly amended grading system.

All the above mentioned modifications in the fifth edition of the ‘blue book’ on CNS tumors will certainly have α substantial impact, directly on the simplification and harmonization of diagnostic procedures and indirectly on the development of more accurate and targeted therapeutic modalities. In addition, extended research on the identification of new molecular markers of diagnostic, therapeutic, and prognostic significance will further contribute to our understanding of the complex pathogenetic mechanisms behind the appearance of various CNS tumors.

This Special Issue aims to publish recent research papers on three important aspects of CNS tumors, namely diagnosis, pathogenesis, and treatment. Therefore, we welcome the submission of valuable research.

Prof. Dr. Dimitrios Kanakis
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Biomedicines is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

• CNS tumors
• diagnosis
• pathogenesis
• treatment
• prognosis
• molecular markers

• Diagnosis, Pathogenesis and Treatment of CNS Tumors in Biomedicines (12 articles)